news.google.com· FiercePharma·· 19 hours agoPickScore71
ESMO: Amgen’s Imdelltra drives massive survival benefit in ‘watershed moment’ for small cell lung cancer - Fierce Pharma
In brief
FiercePharma reports that at the ESMO congress Amgen presented data on Imdelltra in small cell lung cancer, showing a substantial survival benefit, described as a watershed moment for the field.
Why it matters
Reports that Amgen's bispecific antibody Imdelltra showed a substantial survival benefit in small cell lung cancer, potentially a watershed moment for the field.
Source: news.google.com · news.google.com